| 引用本文: | 原少斐,朱林佳,郑维锷.Stathmin及Survivin在非小细胞肺癌中的表达与多西紫杉醇化疗疗效的相关性分析[J].中国现代应用药学,2015,32(10):1188-1193. |
| YUAN Shaofei,ZHU Linjia,ZHENG Wei’e.Relationship Between Expression of Stathmin, Survivin and Chemotherapy Effect of Docetaxel in Advanced Non-small Cell Lung Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(10):1188-1193. |
|
| 摘要: |
| 目的 探讨晚期非小细胞肺癌中Stathmin和Survivin的表达与多西紫杉醇化疗疗效的关系。方法 回顾性分析72例接受多西紫杉醇化疗的晚期非小细胞肺癌患者的临床病理资料。免疫组织化学法检测肿瘤标本Stathmin和Survivin蛋白的表达，并对疗效、不良反应进行分析。结果 Stathmin阳性表达率为65.27%(47/72)，Survivin阳性表达率为76.38%(55/72)。化疗有效率(CR+PR)为51.38%，Stathmin(+)的患者有效率(33.33%)显著低于Stathmin(-)患者(66.67%)(P<0.05)。Survivin(+)组的有效率(38.18%)显著低于Survivin(-)组的76.47%(P<0.05)。联合检测显示：Stathmin(+)且Survivin(+)组有效率为28.94%，中位疾病无进展时间为3.7个月，1年生存率为29.9%，Stathmin(-)且Survivin(-)组有效率为87.50%，中位疾病无进展时间为7.1个月，1年生存率为62.5%，差异均有显著性(P<0.05)。最常见的不良反应为骨髓抑制、消化道反应和脱发。结论 联合检测Stathmin和Survivin的表达可作为多西紫杉醇化疗方案治疗晚期非小细胞肺癌的疗效预测指标之一。 |
| 关键词: 非小细胞肺癌 多西紫杉醇 Stathmin Survivin |
| DOI： |
| 分类号: |
| 基金项目:温州市科技计划项目(Y20130045) |
|
| Relationship Between Expression of Stathmin, Survivin and Chemotherapy Effect of Docetaxel in Advanced Non-small Cell Lung Cancer |
|
YUAN Shaofei, ZHU Linjia, ZHENG Wei’e
|
|
Cancer Center, the Third Affiliated Hospital of Wenzhou Medical University, Rui’an 325000, China
|
| Abstract: |
| OBJECTIVE To investigate the relationship between expression of Stathmin, Survivin and chemotherapy effect of docetaxel in advanced non-small cell lung cancer. METHODS Seventy-two patients with advanced non-small cell lung cancer treating by docetaxel were enrolled in this study and their tumor samples were collected retrospectively for analysis. The expression of Stathmin, Survivin protein in tumor samples was detected by the immunohistochemical method. The data of therapeutical effect and toxicity were collected and analyzed. RESULTS The Stathmin positive staining accounted for 65.27%(47/72). The Survivin positive staining accounted for 76.38%(55/72). The response rate(CR+PR) was 51.38%. The efficiency of patients with over-expression of Stathmin(33.33%) was significant lower than patients with low-expression of Stathmin(66.67%)(P<0.05). The efficiency of patients with over-expression of Survivin(38.18%) was significant lower than patients with low-expression of Survivin(76.47%)(P<0.05). The efficiency, median progress time and 1-survival rate of patients with over-expression of Stathmin and Survivin(28.94%, 3.7 months, 29.9%) were all significant lower than patients with low-expression of Stathmin and Survivin(87.50%, 7.1 months, 62.5%)(P<0.05). The main side-effects were myelosuppression and digestive apparatus toxicity. CONCLUSION The expression of Stathmin and Survivin is associated with chemotherapy effect of docetaxel in advanced non-small cell lung cancer and can be used to detect the sensitivity. |
| Key words: advanced non-small cell lung cancer docetaxel Stathmin Survivin |
